{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:21:11Z","timestamp":1787991671266,"version":"build-2784847793"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T00:00:00Z","timestamp":1493078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"},{"start":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T00:00:00Z","timestamp":1493078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2017,5,23]]},"DOI":"10.1038\/bjc.2017.119","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T20:02:26Z","timestamp":1493150546000},"page":"1402-1407","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma"],"prefix":"10.1038","volume":"116","author":[{"given":"Rachna T","family":"Shroff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Yarchoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna L","family":"Zahurak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Rosner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chimela","family":"Ohaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Sartorius-Mergenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Zinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilofer S","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,25]]},"reference":[{"issue":"11 Suppl","key":"BFbjc2017119_CR1","first-page":"B279","volume":"12","author":"N Azad","year":"2014","unstructured":"Azad N, Ball D, Sherman S, Rudek M, Falchook G, Nelkin B, Janku F, Papadopoulos N, O\u2019Conner A, Ahmed S, Wilky B, Markus S, Gong J, Cosgrove D, Zahurak M, Zinner R, Kurzrock R (2014) Abstract B279: A phase I study determining the safety and tolerability of combination therapy with Pazopanib (P), a VEGFR\/PDGFR\/Raf inhibitor, and GSK1120212 (Trametinib: T), a MEK inhibitor, in advanced solid tumors with expansion cohorts in advanced differentiated thyroid cancer (DTC), cholangiocarcinoma (ChCA), and soft tissue sarcoma (STS). Mol Cancer Ther 12 (11 Suppl): B279.","journal-title":"Mol Cancer Ther"},{"key":"BFbjc2017119_CR2","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.3892\/or.2015.4225","volume":"34","author":"DW Ball","year":"2015","unstructured":"Ball DW, Jin N, Xue P, Bhan S, Ahmed SR, Rosen DM, Schayowitz A, Clark DP, Nelkin BD (2015) Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer. Oncol Rep 34: 2319\u20132324.","journal-title":"Oncol Rep"},{"key":"BFbjc2017119_CR3","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1200\/JCO.2010.33.9473","volume":"29","author":"T Bekaii-Saab","year":"2011","unstructured":"Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JSW, O\u2019Neil BH, Balsom S, Balint C, Liersemann R, Vasko V V, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA (2011) Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 29: 2357\u20132363.","journal-title":"J Clin Oncol"},{"key":"BFbjc2017119_CR4","first-page":"1083","volume":"63","author":"C Benckert","year":"2003","unstructured":"Benckert C, Jonas S, Cramer T, Von Marschall Z, Sch\u00e4fer G, Peters M, Wagner K, Radke C, Wiedenmann B, Neuhaus P, H\u00f6cker M, Rosewicz S (2003) Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 63: 1083\u20131092.","journal-title":"Cancer Res"},{"key":"BFbjc2017119_CR5","doi-asserted-by":"publisher","first-page":"ii140","DOI":"10.1093\/annonc\/mdw237.01","volume":"27","author":"J Bendell","year":"2016","unstructured":"Bendell J, Won KT, Ean CC, Yung-Jue B, Lee C, Desai J, Lewin J, Wallin J, Thakur M, Das, Mwawasi G, Cha E, Infante J (2016) Safety and efficacy of cobimetinib (cobi) and atezolizumab (atezo) in a Phase 1b study of metastatic colorectal cancer (mCRC). Ann Oncol 27: ii140.","journal-title":"Ann Oncol"},{"key":"BFbjc2017119_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/sj.bjc.6605458","volume":"102","author":"C Bengala","year":"2010","unstructured":"Bengala C, Bertolini F, Malavasi N, Boni C, Aitini E, Dealis C, Zironi S, Depenni R, Fontana A, Del Giovane C, Luppi G, Conte P (2010) Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 102: 68\u201372.","journal-title":"Br J Cancer"},{"key":"BFbjc2017119_CR7","doi-asserted-by":"publisher","first-page":"e115383","DOI":"10.1371\/journal.pone.0115383","volume":"9","author":"CR Churi","year":"2014","unstructured":"Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, Zuo M, Zinner R, Hong D, Meric-Bernstam F, Janku F, Crane CH, Mishra L, Vauthey JN, Wolff RA, Mills G, Javle M, Creighton C (2014) Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 9: e115383.","journal-title":"PLoS One"},{"key":"BFbjc2017119_CR8","doi-asserted-by":"publisher","first-page":"910","DOI":"10.4254\/wjh.v7.i6.910","volume":"7","author":"C Dreyer","year":"2015","unstructured":"Dreyer C, Sablin M-P, Bouattour M, Neuzillet C, Ronot M, Dokmak S, Belghiti J, Guedj N, Paradis V, Raymond E, Faivre S (2015) Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy. World J Hepatol 7: 910\u2013915.","journal-title":"World J Hepatol"},{"key":"BFbjc2017119_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","volume":"44","author":"PJR Ebert","year":"2016","unstructured":"Ebert PJR, Cheung J, Yang Y, McNamara E, Hong R, Moskalenko M, Gould SE, Maecker H, Irving BA, Kim JM, Belvin M, Mellman I (2016) MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity 44: 609\u2013621.","journal-title":"Immunity"},{"key":"BFbjc2017119_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228\u2013247.","journal-title":"Eur J Cancer"},{"key":"BFbjc2017119_CR11","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1007\/s10637-011-9719-0","volume":"30","author":"AB El-Khoueiry","year":"2012","unstructured":"El-Khoueiry AB, Rankin CJ, Ben-Josef E, Lenz H-J, Gold PJ, Hamilton RD, Govindarajan R, Eng C, Blanke CD (2012) SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs 30: 1646\u20131651.","journal-title":"Invest New Drugs"},{"key":"BFbjc2017119_CR12","first-page":"220","volume":"30","author":"RS Finn","year":"2012","unstructured":"Finn RS, Javle MM, Tan BR, Weekes CD, Bendell JC, Patnaik A, Khan GN, Laheru D, Anderson L, Christy-Bittel JL, Barrett E, Guthrie K, Litwiler KS, Bekaii-Saab TS (2012) A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer. ASCO Meet Abstr 30: 220.","journal-title":"ASCO Meet Abstr"},{"key":"BFbjc2017119_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov L V., Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JMG, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin A-M, Patel K, Schadendorf D (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367: 107\u2013114.","journal-title":"N Engl J Med"},{"key":"BFbjc2017119_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/jnci\/82.1.4","volume":"82","author":"J Folkman","year":"1990","unstructured":"Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4\u20136.","journal-title":"J Natl Cancer Inst"},{"key":"BFbjc2017119_CR15","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nrc3627","volume":"13","author":"HL Goel","year":"2013","unstructured":"Goel HL, Mercurio AM (2013) VEGF targets the tumour cell. Nat Rev Cancer 13: 871\u2013882.","journal-title":"Nat Rev Cancer"},{"key":"BFbjc2017119_CR16","first-page":"800","volume":"33","author":"L Goyal","year":"2015","unstructured":"Goyal L, Yurgelun MB, Abrams TA, Kwak EL, Cleary JM, Knowles M, Regan E, Gisondi A, Sheehan S, Zheng H, Zhu AX (2015) A phase II trial of cabozantinib (XL-184) in patients with advanced cholangiocarcinoma. ASCO Meet Abstr 33: 800.","journal-title":"ASCO Meet Abstr"},{"key":"BFbjc2017119_CR17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/1078-0432.CCR-10-1603","volume":"17","author":"B Gril","year":"2011","unstructured":"Gril B, Palmieri D, Qian Y, Smart D, Ileva L, Liewehr DJ, Steinberg SM, Steeg PS (2011) Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. Clin Cancer Res 17: 142\u2013153.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2017119_CR18","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","volume":"13","author":"JR Infante","year":"2012","unstructured":"Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HA, Messersmith WA (2012) Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 13: 773\u2013781.","journal-title":"Lancet Oncol"},{"key":"BFbjc2017119_CR19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457\u2013481.","journal-title":"J Am Stat Assoc"},{"key":"BFbjc2017119_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/13651820801992641","volume":"10","author":"SA Khan","year":"2008","unstructured":"Khan SA, Toledano MB, Taylor-Robinson SD (2008) Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 10: 77\u201382.","journal-title":"HPB (Oxford)"},{"key":"BFbjc2017119_CR21","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1093\/annonc\/mdu162","volume":"25","author":"A Lamarca","year":"2014","unstructured":"Lamarca A, Hubner RA, David Ryder W, Valle JW (2014) Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol 25: 2328\u20132338.","journal-title":"Ann Oncol"},{"key":"BFbjc2017119_CR22","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1126\/science.2479986","volume":"246","author":"DW Leung","year":"1989","unstructured":"Leung DW, Cachianes G, Kuang WJ, Goeddel D V, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306\u20131309.","journal-title":"Science"},{"key":"BFbjc2017119_CR23","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","volume":"21","author":"L Liu","year":"2015","unstructured":"Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, Yang J, Seestaller-Wehr L, Zhang SY, Hopson C, Tsvetkov L, Jing J, Zhang S, Smothers J, Hoos A (2015) The BRAF and MEK inhibitors dabrafenib and trametinib: Effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res 21: 1639\u20131651.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2017119_CR24","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1200\/JCO.2010.28.4075","volume":"28","author":"SJ Lubner","year":"2010","unstructured":"Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, Philip PA, Picus J, Yong W-P, Horvath L, Van Hazel G, Erlichman CE, Holen KD (2010) Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol 28: 3491\u20133497.","journal-title":"J Clin Oncol"},{"key":"BFbjc2017119_CR25","unstructured":"National Institute of Cancer (2009) Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events v4.0 (CTCAE). NIH Publ 0\u201371."},{"key":"BFbjc2017119_CR26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/01.coc.0000204402.29830.08","volume":"29","author":"BK Park","year":"2006","unstructured":"Park BK, Paik Y-H, Park JY, Park KH, Bang S, Park SW, Chung JB, Park YN, Song SY (2006) The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma. Am J Clin Oncol 29: 138\u2013142.","journal-title":"Am J Clin Oncol"},{"key":"BFbjc2017119_CR27","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1053\/jhep.2001.25087","volume":"33","author":"T Patel","year":"2001","unstructured":"Patel T (2001) Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33: 1353\u20131357.","journal-title":"Hepatology"},{"key":"BFbjc2017119_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long G V., Flaherty K, Nathan P, Ribas A, Martin A-M, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372: 30\u201339.","journal-title":"N Engl J Med"},{"key":"BFbjc2017119_CR29","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","volume":"26","author":"PJ Roberts","year":"2007","unstructured":"Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291\u20133310.","journal-title":"Oncogene"},{"key":"BFbjc2017119_CR30","first-page":"408","volume":"5","author":"JE Rogers","year":"2014","unstructured":"Rogers JE, Law L, Nguyen VD, Qiao W, Javle MM, Kaseb A, Shroff RT (2014) Second-line systemic treatment for advanced cholangiocarcinoma. J Gastrointest Oncol 5: 408\u2013413.","journal-title":"J Gastrointest Oncol"},{"key":"BFbjc2017119_CR31","doi-asserted-by":"publisher","first-page":"6470","DOI":"10.3748\/wjg.v13.i48.6470","volume":"13","author":"KJ Schmitz","year":"2007","unstructured":"Schmitz KJ, Lang H, Wohlschlaeger J, Sotiropoulos GC, Reis H, Schmid KW, Baba HA (2007) AKT and ERK1\/2 signaling in intrahepatic cholangiocarcinoma. World J Gastroenterol 13: 6470\u20136477.","journal-title":"World J Gastroenterol"},{"key":"BFbjc2017119_CR32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1055\/s-2004-828889","volume":"24","author":"Y Shaib","year":"2004","unstructured":"Shaib Y, El-Serag HB (2004) The epidemiology of cholangiocarcinoma. Semin Liver Dis 24: 115\u2013125.","journal-title":"Semin Liver Dis"},{"key":"BFbjc2017119_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66: 7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"BFbjc2017119_CR34","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarb\u00e1 JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28: 1061\u20131068.","journal-title":"J Clin Oncol"},{"key":"BFbjc2017119_CR35","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362: 1273\u20131281.","journal-title":"N Engl J Med"},{"key":"BFbjc2017119_CR36","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT van der Graaf","year":"2012","unstructured":"van der Graaf WT, Blay J-Y, Chawla SP, Kim D-W, Bui-Nguyen B, Casali PG, Sch\u00f6ffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379: 1879\u20131886.","journal-title":"Lancet"},{"key":"BFbjc2017119_CR37","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.jhep.2009.01.024","volume":"50","author":"C Wang","year":"2009","unstructured":"Wang C, Maass T, Krupp M, Thieringer F, Strand S, W\u00f6rns MA, Barreiros A-P, Galle PR, Teufel A (2009) A systems biology perspective on cholangiocellular carcinoma development: focus on MAPK-signaling and the extracellular environment. J Hepatol 50: 1122\u20131131.","journal-title":"J Hepatol"},{"key":"BFbjc2017119_CR38","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.jhep.2004.07.016","volume":"41","author":"J-H Yoon","year":"2004","unstructured":"Yoon J-H, Gwak G-Y, Lee H-S, Bronk SF, Werneburg NW, Gores GJ (2004) Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol 41: 808\u2013814.","journal-title":"J Hepatol"},{"key":"BFbjc2017119_CR39","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/sj.bjc.6604129","volume":"98","author":"D Yoshikawa","year":"2008","unstructured":"Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, Hirohashi S, Shibata T (2008) Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 98: 418\u2013425.","journal-title":"Br J Cancer"}],"updated-by":[{"DOI":"10.1038\/bjc.2017.418","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T00:00:00Z","timestamp":1515456000000}}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2017119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2017119","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bjc.2017.119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2017119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:37:33Z","timestamp":1684417053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2017119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,25]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,5,23]]}},"alternative-id":["BFbjc2017119"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2017.119","relation":{"erratum":[{"id-type":"doi","id":"10.1038\/bjc.2017.418","asserted-by":"object"}]},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,25]]},"assertion":[{"value":"3 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2017","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}